S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches

Peak Bio (PKBO) Competitors

$0.0020
0.00 (0.00%)
(As of 03/1/2024 ET)

PKBO vs. IGNY, STAB, NOVN, NOVNQ, HGEN, VRAYQ, AHPI, SCPS, CALA, and GNCAQ

Should you be buying Peak Bio stock or one of its competitors? The main competitors of Peak Bio include Ignyte Acquisition (IGNY), Statera Biopharma (STAB), Novan (NOVN), NVN Liquidation (NOVNQ), Humanigen (HGEN), ViewRay (VRAYQ), Allied Healthcare Products (AHPI), Scopus BioPharma (SCPS), Calithera Biosciences (CALA), and Genocea Biosciences (GNCAQ). These companies are all part of the "medical" sector.

Peak Bio vs.

Peak Bio (NASDAQ:PKBO) and Ignyte Acquisition (NASDAQ:IGNY) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, community ranking, earnings, analyst recommendations, dividends and valuation.

In the previous week, Peak Bio's average media sentiment score of 0.00 equaled Ignyte Acquisition'saverage media sentiment score.

Company Overall Sentiment
Peak Bio Neutral
Ignyte Acquisition Neutral

Ignyte Acquisition has lower revenue, but higher earnings than Peak Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Peak Bio$610K0.07-$13.09MN/AN/A
Ignyte AcquisitionN/AN/A-$490KN/AN/A

Ignyte Acquisition's return on equity of 365.46% beat Peak Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Peak BioN/A N/A -103.78%
Ignyte Acquisition N/A 365.46%-0.83%

61.1% of Ignyte Acquisition shares are owned by institutional investors. 19.9% of Peak Bio shares are owned by insiders. Comparatively, 19.9% of Ignyte Acquisition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Peak Bio has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, Ignyte Acquisition has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500.

Peak Bio received 1 more outperform votes than Ignyte Acquisition when rated by MarketBeat users.

CompanyUnderperformOutperform
Peak BioOutperform Votes
1
100.00%
Underperform Votes
No Votes
Ignyte AcquisitionN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Peak Bio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Ignyte Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

Ignyte Acquisition beats Peak Bio on 6 of the 8 factors compared between the two stocks.


Get Peak Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for PKBO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PKBO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PKBO vs. The Competition

MetricPeak BioBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$50,000.00$2.63B$5.04B$7.60B
Dividend YieldN/A2.37%2.81%3.87%
P/E RatioN/A31.54239.7117.51
Price / Sales0.07165.473,269.63186.98
Price / CashN/A29.9398.0354.93
Price / Book-0.014.464.594.71
Net Income-$13.09M-$52.45M$114.86M$211.49M
7 Day PerformanceN/A5.82%5.64%3.36%
1 Month PerformanceN/A15.68%11.13%6.69%
1 Year PerformanceN/A12.50%13.96%8.87%

Peak Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IGNY
Ignyte Acquisition
0 of 5 stars
$0.00
flat
N/AN/A$15,000.00N/A0.00N/AGap Down
STAB
Statera Biopharma
0 of 5 stars
$0.00
flat
N/A-97.6%$33,000.00$1.49M0.0046Gap Down
NOVN
Novan
0.8907 of 5 stars
$0.00
flat
$8.00
+888,788.9%
-99.9%$25,000.00$24.71M0.0090Analyst Report
NOVNQ
NVN Liquidation
0 of 5 stars
$0.00
flat
N/AN/A$25,000.00$23.68M0.0090News Coverage
HGEN
Humanigen
0 of 5 stars
N/A$0.50
+∞
N/A$24,000.00$1.70M0.006News Coverage
VRAYQ
ViewRay
0 of 5 stars
N/AN/AN/A$20,000.00$102.21M0.00295
AHPI
Allied Healthcare Products
0 of 5 stars
N/AN/AN/A$16,000.00$27.05M0.00189
SCPS
Scopus BioPharma
0 of 5 stars
$0.00
flat
N/A-97.7%$84,000.00N/A0.0013Gap Down
CALA
Calithera Biosciences
0 of 5 stars
$0.03
flat
N/A-68.3%$122,000.00$9.75M0.008
GNCAQ
Genocea Biosciences
0 of 5 stars
N/AN/AN/A$10,000.00$1.64M0.0074

Related Companies and Tools

This page (NASDAQ:PKBO) was last updated on 3/2/2024 by MarketBeat.com Staff